Synergistic L-ergothioneine and NMN Composition for Cellular Health
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions fail to effectively regulate excessive reactive oxygen species (ROS) production in cells and concurrently repair DNA damage, leading to cellular dysfunction and various diseases such as oxidative stress-induced pregnancy complications, liver, and kidney diseases.
Innovation Solution
A synergistic composition of L-ergothioneine and nicotinamide mononucleotide, where L-ergothioneine acts as a ROS scavenger and inflammation suppressor, and nicotinamide mononucleotide serves as a DNA repair facilitator, regulating Nrf2 expression and reducing cell apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single bioactive agents are used, then simplicity of composition is maintained, but effectiveness in simultaneously scavenging ROS and repairing DNA is insufficient
Solution Approach 1:
The patent combines two distinct bioactive agents (L-ergothioneine for ROS scavenging and NMN for DNA repair) into a single synergistic composition. This merging allows the composition to simultaneously address multiple cellular damage mechanisms that a single agent could not effectively tackle alone, thereby resolving the contradiction between simplicity and effectiveness.
Solution Approach 2:
The invention creates a composite pharmaceutical composition where L-ergothioneine and NMN work together in specific ratios (1:1 to 1:80). This composite approach leverages the complementary mechanisms of both agents - L-ergothioneine's antioxidant properties and NMN's DNA repair facilitation - to achieve enhanced therapeutic effects that neither component could provide alone.
2Reliability
If conventional pharmaceutical compositions are used, then ease of manufacture is maintained, but ability to regulate excessive ROS production and repair DNA damage simultaneously is insufficient
Solution Approach 1:
The patent specifies optimal concentration ranges for L-ergothioneine (1-250 mg) and NMN (1-500 mg) to achieve synergistic effects. By optimizing these parameters, the composition maximizes therapeutic effectiveness while maintaining feasibility for pharmaceutical manufacturing. The defined ratio range (1:1 to 1:80) provides flexibility for manufacturing while ensuring efficacy.
3Reliability
If high doses of single agents are used, then therapeutic effectiveness is improved, but risk of side effects and cellular toxicity increases
Solution Approach 1:
L-ergothioneine acts as a protective intermediary that scavenges ROS and reduces oxidative stress, thereby creating a safer environment for NMN to facilitate DNA repair. This intermediary role of L-ergothioneine mitigates the potential toxicity of high-dose treatments by neutralizing harmful reactive oxygen species that could otherwise interfere with DNA repair processes or cause cellular damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces inflammation, repairs DNA damage, and improves cellular health by regulating ROS production, thereby enhancing overall cellular function and addressing conditions like pregnancy complications, liver, and kidney diseases.
Implementation Method 1
L-ergothioneine acts as a ROS scavenger and inflammation suppressor
Implementation Method 2
nicotinamide mononucleotide serves as a DNA repair facilitator, regulating Nrf2 expression and reducing cell apoptosis
Data Source
AI summary
The present invention discloses herein a synergistic composition(s) of bioactive agents for optimizing cellular health. Particularly, a synergistic bioactive composition for optimizing cellular health, wherein the composition comprising therapeutic blend of betaine of thiol histidine and sirtuin activator(s) or salts thereof present in the ratio of 1:0.5 to 1:90, along with pharmaceutically acceptable excipients. In another embodiment, the invention discloses novel synergistic nutritional composition comprising synergistic combination of bioactives L-ergothioneine and nicotinamide mononucleotide chloride present in the ratio ranges from 1:1 to 1:80. The present invention provides promising and effective nutritional composition for improving cellular health by regulating expression of transcriptional factor, pro-inflammatory cytokines, and reducing cell apoptosis, ROS level and DNA damage in the cell.